Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. 1. Juni 2011 van de Velde, C.J.., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E., others, 2011. Lancet 377, 321–331. doi:10.1016/S0140-6736(10)62312-4 Abstract REASON: TKI sensitive EGFR mutation status and associated characteristics of advanced NSCLC patients – Results from a German registry. Thomas, M., Eberhardt, W., Graf von der Schluenburg, J., Dietel, M., Schirmacher, P., Gutendirf, B., Schaller, F., Schütte, W., 2011. Onkologie 34 (suppl 6)(V451), 124. Weiterlesen Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with sorafenib and paclitaxel by initial ramp-up dose escalation (PASO). Overkamp, F., Steffens, C., Abenhardt, W., Lerchenmüller, C., Nusch, A., Göhler, T., Groschek, M., Hegewisch-Becker, S., Marschner, N., Rösel, S., Salat, C., Decker, T., 2011. Weiterlesen